These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
752 related articles for article (PubMed ID: 32027536)
1. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536 [No Abstract] [Full Text] [Related]
2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792 [TBL] [Abstract][Full Text] [Related]
3. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies. Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281 [TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Choi BD; Maus MV; June CH; Sampson JH Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future. Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y Front Immunol; 2020; 11():594271. PubMed ID: 33224149 [TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. Sengupta S; Katz SC; Sengupta S; Sampath P Cancer Lett; 2018 Oct; 433():131-139. PubMed ID: 29959057 [TBL] [Abstract][Full Text] [Related]
8. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H Cells; 2020 Apr; 9(4):. PubMed ID: 32316275 [TBL] [Abstract][Full Text] [Related]
9. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model. Song Y; Liu Q; Zuo T; Wei G; Jiao S Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131 [TBL] [Abstract][Full Text] [Related]
11. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912 [TBL] [Abstract][Full Text] [Related]
12. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Zhou S; Sun H; Choi SI; Yin J Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692 [TBL] [Abstract][Full Text] [Related]
13. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives. Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H Cells; 2024 Apr; 13(9):. PubMed ID: 38727262 [TBL] [Abstract][Full Text] [Related]
14. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Li X; Zhao L; Li W; Gao P; Zhang N Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509 [TBL] [Abstract][Full Text] [Related]
16. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? Prinzing BL; Gottschalk SM; Krenciute G Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078 [TBL] [Abstract][Full Text] [Related]
18. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H Front Immunol; 2018; 9():3062. PubMed ID: 30740109 [TBL] [Abstract][Full Text] [Related]
19. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Majd N; de Groot J Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484 [No Abstract] [Full Text] [Related]
20. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Zhang P; Zhang Y; Ji N Front Immunol; 2022; 13():927132. PubMed ID: 35874698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]